Amarin's Drug Launch: Mega Hit or Epic Fail?

Biotech Amarin (NASDAQ: AMRN  ) is gearing up for the launch of its triglyceride-lowering drug Vascepa. The drug is slated to hit the market in the coming weeks and will go up against GlaxoSmithKline's (NYSE: GSK  ) Lovaza and AbbVie's (NYSE: ABBV  ) drugs Tricor and Trilipix. Investors are waiting to see whether Vascepa can fulfill the blockbuster destiny many predict, or if the company will fall flat on its face. Many biotechs of late -- including obesity drugmaker VIVUS (NASDAQ: VVUS  ) and cancer-focused biotech Dendreon (NASDAQ: DNDN  )  -- have shown that launching a drug is much, much harder than it looks.

So, investors -- will Amarin succeed or fail?

In this video, health care analyst Max Macaluso discusses his outlook for this stock as the launch date looms.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the Vascepa's success is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with this premium research report. Click here now to keep reading.


Read/Post Comments (2) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 08, 2013, at 3:01 PM, skm1965 wrote:

    Agree with your comments. I also heard the whole presentation.

  • Report this Comment On January 09, 2013, at 10:30 AM, yazzbro wrote:

    I think a lot of investors were looking for the quick money with a buyout of AMRN. That of course, hasn't happened yet. I don't discount that it wont either. However, if the launch is even somewhat successful I am not sure why AMRN would want to be bought out. I think switching their patients to Vascepa from Lovaza should be a no brainer for most Doctors. I am not saying that Vascepa is going to sell itself but, it shouldn't be a tough sell either. So I am all for the go it alone strategy at this point. I think Big Pharm may have missed their chance to get AMRN for rock bottom prices. If the launch is successful and the Anchor gets approved(Which most likely it will.) I can't see AMRN selling the company for less than $65 a share. I was for the buyout big time before but, now I think I am more interested in them going it alone.. I think if investors have a bit more patience I think in the next 5 years AMRN could be sitting at about $75 to a $100 a share. Cheers and happy trading..

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2185151, ~/Articles/ArticleHandler.aspx, 10/23/2014 12:40:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement